Dyne Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:DYN) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities 74.63 M84.33 M105.89 M94.7 M90.78 M 375.71 M Cash from investing activities 19.4 M16.01 M1.46 M6.77 M21.5 M 45.74 M Cash from financing activities 18.01 M3.64 M141.24 M100.77 M217.33 M 462.98 M Free cash flow 74.38 M83.26 M104.91 M94.64 M90.38 M 373.2 M

Nouvelles

Le PDG de Sarepta va quitter le navire après une année "tumultueuse" | Benzinga France

Résultats de Dyne Therapeutics : calendrier de dépôt DMD en ligne de mire

Dyne Therapeutics earnings ahead: DMD filing timeline in focus

Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?

Dyne Therapeutics: 2026 Catalysts Point To Further Upside (NASDAQ:DYN)

Le Japon accorde le statut de médicament orphelin au traitement DM1 de Dyne

Japan grants orphan drug status to Dyne’s DM1 treatment

Dyne Therapeutics, Inc. (DYN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Dyne Therapeutics, Inc. (DYN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:DYN) 2026-01-14

Dyne Therapeutics nomme Vikram Karnani à son conseil d’administration

Dyne Therapeutics appoints Vikram Karnani to board of directors

Dyne Therapeutics lève 402,5 millions d’euros lors d’une offre publique élargie